Given limited data from Asian populations on use of the biomarker, or comprehensive evaluation of the utility of NT-proBNP for various cardiorenal complications in diabetes, we undertook this study to evaluate the clinical utility of NT-proBNP for predicting cardiorenal complications in a longitudinal cohort of Chinese individuals with type 2 diabetes, including comparison of its performance in precision prognostics compared with established clinical risk factors. This evidence concerns the gene NPPB and diabetes mellitus.